Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Cancer Chemother Pharmacol
; 85(4): 641-650, 2020 04.
Article
in En
| MEDLINE
| ID: mdl-32157412
Full text:
1
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Adenocarcinoma
/
Antineoplastic Combined Chemotherapy Protocols
/
Biomarkers, Tumor
/
CA-19-9 Antigen
/
Carcinoma, Pancreatic Ductal
/
Duration of Therapy
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2020
Type:
Article
Affiliation country:
Italy